M
Michael C. Soulen
Researcher at University of Pennsylvania
Publications - 311
Citations - 14169
Michael C. Soulen is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Embolization & Hepatocellular carcinoma. The author has an hindex of 59, co-authored 294 publications receiving 12012 citations. Previous affiliations of Michael C. Soulen include Chestnut Hill College & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update
Muneeb Ahmed,Luigi Solbiati,Christopher L. Brace,David J. Breen,Matthew R. Callstrom,J. William Charboneau,Min-hua Chen,Byung Ihn Choi,Thierry de Baere,Gerald D. Dodd,Damian E. Dupuy,Debra A. Gervais,David Gianfelice,Alice Gillams,Fred T. Lee,Edward Leen,Riccardo Lencioni,Peter Littrup,T. Livraghi,David S.K. Lu,John P. McGahan,Maria Franca Meloni,Boris Nikolic,Philippe L. Pereira,Ping Liang,Hyunchul Rhim,Steven C. Rose,Riad Salem,Constantinos T. Sofocleous,Stephen B. Solomon,Michael C. Soulen,Masatoshi Tanaka,Thomas J. Vogl,Bradford J. Wood,S. Nahum Goldberg +34 more
TL;DR: This updated consensus document provides a framework that will facilitate the clearest communication among investigators regarding ablative technologies and improve the precision of communications in this field, leading to more accurate comparison of technologies and results, and ultimately to improved patient outcomes.
Journal ArticleDOI
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty,Andrew R. Haas,Marcela V. Maus,Drew A. Torigian,Michael C. Soulen,Gabriela Plesa,Anne Chew,Yangbing Zhao,Bruce L. Levine,Steven M. Albelda,Michael Kalos,Carl H. June +11 more
TL;DR: Findings support the development of mRNA CAR-based strategies for carcinoma and other solid tumors by showing the potential of using mRNA-engineered T cells to evaluate, in a controlled manner, potential off-tumor on-target toxicities and showing that short-lived CAR T cells can induce epitope spreading and mediate antitumor activity in patients with advanced cancer.
Journal ArticleDOI
Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough
Gerald D. Dodd,Michael C. Soulen,Robert A. Kane,Tito Livraghi,William R. Lees,Yasuyuki Yamashita,Alison R. Gillams,Okkes Ibrahim Karahan,Hyunchul Rhim +8 more
TL;DR: With continued improvement in technology and increasing clinical experience, one or more of these minimally invasive techniques may soon challenge surgical resection as the treatment of choice for patients with limited hepatic tumor.
Journal ArticleDOI
Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data.
Riccardo Lencioni,Thierry de Baere,Michael C. Soulen,William S. Rilling,Jean Francois H. Geschwind +4 more
TL;DR: In a systematic literature review, survival figures of HCC patients undergoing lipiodol TACE appear to be in line with those reported in previous RCTs, and no new or unexpected safety concerns were identified.
Journal ArticleDOI
Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.
Muneeb Ahmed,Luigi Solbiati,Christopher L. Brace,David J. Breen,Matthew R. Callstrom,J. William Charboneau,Min-hua Chen,Byung Ihn Choi,Thierry de Baere,Gerald D. Dodd,Damian E. Dupuy,Debra A. Gervais,David Gianfelice,Alice Gillams,Fred T. Lee,Edward Leen,Riccardo Lencioni,Peter Littrup,Tito Livraghi,David S.K. Lu,John P. McGahan,Maria Franca Meloni,Boris Nikolic,Philippe L. Pereira,Ping Liang,Hyunchul Rhim,Steven C. Rose,Riad Salem,Constantinos T. Sofocleous,Stephen B. Solomon,Michael C. Soulen,Masatoshi Tanaka,Thomas J. Vogl,Bradford J. Wood,S. Nahum Goldberg +34 more
TL;DR: This updated consensus document provides a framework that will facilitate the clearest communication among investigators regarding ablative technologies and improve the precision of communications in this field, leading to more accurate comparison of technologies and results, and ultimately to improved patient outcomes.